Janssen, Araxes collaborate on cancer drug development

02/28/2013 | Genetic Engineering & Biotechnology News

Janssen Biotech and Araxes Pharma agreed to work on oncology drugs against a certain target. Araxes, which will be initially in charge of development, will receive an upfront fee, research funding, milestone fees and sales royalties. Janssen will get the rights to market the products arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care